A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.
Author(s): Shao D, Lin Y, Liu J, Wan L, Liu Z, Cheng S, Fei L, Deng R, Wang J, Chen X, Liu L, Gu X, Liang W, He P, Wang J, Ye M, He J
Publication: Sci Rep, 2016, Vol. 6, Page 22338
PubMed ID: 26936516 PubMed Review Paper? No
Purpose of Paper
This paper compared genotyping results by next-generation sequencing (NGS) with those by conventional methods in formalin-fixed paraffin embedded (FFPE) lung adenocarcinoma specimens.
Conclusion of Paper
NGS detected all mutations identified by conventional methods as well as some additional ones including therapeutically-actionable mutations in some specimens.
Studies
-
Study Purpose
This study compared genotyping results by next-generation sequencing with those by conventional methods in 119 FFPE lung adenocarcinoma specimens. After xylene deparaffinization, DNA was extracted using the QIAamp DNA FFPE tissue kit. A panel of 145 genes was sequenced using an Ion Proton Sequencer. The results were compared with those obtained previously using amplification refractory mutation system (ARMS)-PCR, fluorescent in situ hybridization (FISH), or Sanger Sequencing.
Summary of Findings:
NGS detected all mutations identified by ARMS-PCR, FISH, or Sanger Sequencing in 61 specimens, including those in specimens containing only 10-15% tumor cells. However, additional mutations were identified by NGS in some specimens that were not identified by ARMS-PCR or FISH. Further, using an additional 58 specimens, NGS identified 1.4 times as many actionable mutations as ARMS-PCR or FISH.
Biospecimens
Preservative Types
- Formalin
Diagnoses:
- Neoplastic - Carcinoma
Platform:
Analyte Technology Platform DNA Next generation sequencing DNA PCR DNA FISH DNA DNA sequencing Pre-analytical Factors:
Classification Pre-analytical Factor Value(s) Next generation sequencing Specific Technology platform Sanger sequencing
ARMS-PCR
FISH